TORONTO, April 25, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that management will host a corporate presentation at the 2023 Bloom Burton & Co.


Previous articleBetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California
Next articlePT407 – The Planet, Psychedelics, and Psyche: Optimism in Ecology